These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12215063)

  • 21. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study.
    Jafarinia M; Mohammadi MR; Modabbernia A; Ashrafi M; Khajavi D; Tabrizi M; Yadegari N; Akhondzadeh S
    Hum Psychopharmacol; 2012 Jul; 27(4):411-8. PubMed ID: 22806822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
    McGough JJ; Pataki CS; Suddath R
    Expert Rev Neurother; 2005 Jul; 5(4):437-41. PubMed ID: 16026226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
    Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
    Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
    Quinn D; Wigal S; Swanson J; Hirsch S; Ottolini Y; Dariani M; Roffman M; Zeldis J; Cooper T
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1422-9. PubMed ID: 15502602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder.
    Zheng Y; Liang JM; Gao HY; Yang ZW; Jia FJ; Liang YZ; Fang F; Li R; Xie SN; Zhuo JM
    Chin Med J (Engl); 2015 Nov; 128(22):2988-97. PubMed ID: 26608976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate.
    Wang LJ; Chen CK; Huang YS
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):246-53. PubMed ID: 25574708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parental quality of life and depressive mood following methylphenidate treatment of children with attention-deficit hyperactivity disorder.
    Kim Y; Kim B; Chang JS; Kim BN; Cho SC; Hwang JW
    Psychiatry Clin Neurosci; 2014 Jul; 68(7):506-14. PubMed ID: 24417707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
    Silva R; Muniz R; McCague K; Childress A; Brams M; Mao A
    Psychopharmacol Bull; 2008; 41(1):19-33. PubMed ID: 18362868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults.
    Kuperman S; Perry PJ; Gaffney GR; Lund BC; Bever-Stille KA; Arndt S; Holman TL; Moser DJ; Paulsen JS
    Ann Clin Psychiatry; 2001 Sep; 13(3):129-34. PubMed ID: 11791949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gender Differences in the Behavioral Symptoms and Neuropsychological Performance of Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate: A Two-Year Follow-up Study.
    Wang LJ; Chen CK; Huang YS
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):501-8. PubMed ID: 26262904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
    Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
    Pheils J; Ehret MJ
    Am J Health Syst Pharm; 2021 May; 78(10):840-849. PubMed ID: 33954419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials.
    Castells X; Cunill R; Capellà D
    Eur J Clin Pharmacol; 2013 Mar; 69(3):347-56. PubMed ID: 22983311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder.
    Gorman EB; Klorman R; Thatcher JE; Borgstedt AD
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):808-16. PubMed ID: 16832317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.